Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

about

Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study

P2860

Q58112904-F7415C2E-9047-4100-B148-B3342151254B

P2860

Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

Item

http://www.wikidata.org/entity/Q45067466

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

@en

Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

@nl

type

Item

label

Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

@en

Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

@nl

prefLabel

Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

@en

Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

@nl

P1476

Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

@en

P2093

Denise K Lowe

http://www.w3.org/2001/XMLSchema#string

Kylie Weigel

http://www.w3.org/2001/XMLSchema#string

May T Aziz

http://www.w3.org/2001/XMLSchema#string

Payal P Kakadiya

http://www.w3.org/2001/XMLSchema#string

Samantha M Kush

http://www.w3.org/2001/XMLSchema#string

P2860

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.

Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion.

Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.

P304

1060028017732586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028017732586

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28914546

http://www.w3.org/2001/XMLSchema#string

Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

about

P2860

P2860

Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698